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Abstract 
Background   This register-based observational study compares dabigatran to warfarin for 
secondary stroke prevention in atrial fibrillation patients among both ‘new starters’ on dabigatran 
and ‘switchers’ to dabigatran from warfarin. 
Methods   We identified in nationwide Danish registries 2,398 patients with atrial fibrillation and a 
history of stroke/TIA, making a first-time purchase of dabigatran 110mg bid (D110) and 150mg bid 
(D150). Patients were categorized as either vitamin K antagonist (VKA) naïve or experienced. 
Warfarin controls were identified using a complete (for VKA-naïve dabigatran patients) or matched 
sampling approach (for VKA-experienced dabigatran patients). Subjects were followed for an 
average of 12.6 months for stroke and transient ischemic attacks. Confounder-adjusted Cox 
regression models were used to compare event rates between treatments.  
Results   Among patients with a history of stroke/ transient ischemic attack and prior VKA 
experience, switching to dabigatran was associated with an increased stroke/ transient ischemic 
attack rate for both dabigatran doses compared to continuing on warfarin (D110 hazard ratio [HR] 
1.99, 95% confidence interval [CI]: 1.42-2.78; D150 HR 2.34, 95% CI: 1.60-3.41).  
Among prior stroke/ transient ischemic attack patients who were new starters on dabigatran or 
warfarin, the rate of stroke/ transient ischemic attack for both doses of dabigatran was similar to or 
lower than warfarin (D110 HR 0.64, 95% CI: 0.50-0.80; D150 HR 0.92, 95% CI: 0.73-1.15). 
Conclusions   In this register-based study, VKA-experienced patients with a history of stroke or 
transient ischemic attack who switched to dabigatran therapy had an increased rate of stroke 
compared to patients persisting with warfarin therapy.  
 
Keywords: atrial fibrillation, stroke, antithrombotic therapy, dabigatran, warfarin, comparative 
effectiveness  
 
Abbreviations: HR = hazard ratio; VKA = vitamin K antagonist   
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Introduction 
The risk of stroke in atrial fibrillation patients is high, especially among patients with a history of 
ischemic stroke or transient ischemic attack1. Stroke prevention in atrial fibrillation has 
conventionally involved anticoagulant therapy with vitamin K antagonists (VKA) such as warfarin2, 
but a narrow therapeutic range makes optimal treatment challenging. Dabigatran etexilate is a direct 
thrombin inhibitor whose rapid and predictable response can mitigate the complexity of 
conventional anticoagulant therapy. Trials and subsequent observational studies in mixed patient 
populations have shown dabigatran to provide comparable or slightly improved protection against 
stroke and systemic embolism, without compromising bleeding safety3–5. 
Trial-based findings within the clinically important subgroup of patients with prior stroke have been 
consistent with the overall efficacy and safety profile results for dabigatran. A predefined sub-study 
of the RE-LY study (Randomized Evaluation of Long Term Anticoagulant Therapy) found similar 
or slightly lower rates of stroke and systemic embolism among patients with a prior stroke/transient 
ischemic attack (2.78% for warfarin, 2.32% for dabigatran 110 mg bid; 2.07% for dabigatran 150 
mg bid)6. In an indirect comparison of three new oral anticoagulants (apixaban, rivaroxaban and 
dabigatran) using secondary prevention (previous stroke) trial subgroups7, we found that dabigatran 
had similar efficacy to warfarin for stroke/systemic embolism, ischemic stroke, and all-cause 
mortality. However, the extent to which these trial-based subgroup findings transfer to a practical 
clinical setting is currently unclear.  
Analysis of observational data, while insufficient for providing unequivocal treatment 
recommendations, can provide valuable insight into medication effectiveness in a practical clinical 
setting.  The present nationwide observational study shares design and data similarities with recent 
studies on myocardial infarction and bleeding risk with dabigatran and warfarin, but in the present 
study we focus only on patients with previous stroke8,9. Specifically, we used prescription purchase 
data to assess the effectiveness of dabigatran relative to warfarin for secondary prevention in a real-
world atrial fibrillation population with a history of stroke or transient ischemic attack. A 
substantial proportion of dabigatran initiators are patients who are switched from warfarin, so-called 
warfarin survivors10. In RE-LY, no differences were found in the prognosis between such warfarin 
survivors and new starters11. However, this finding may not transfer to a non-trial setting with more 
autonomous treatment management, particularly not in a high-risk patient group. Accordingly, we 
assessed the risk of stroke among patients with a history of stroke/ transient ischemic attack 
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separately within the stratum of ‘switchers’ from warfarin to dabigatran (compared to warfarin 
persisters); and within the stratum of ‘new starters’ on dabigatran (compared to new starters on 
warfarin).  
 
Methods 
We used the civil registration number assigned to all Danish residents to link three nationwide 
databases: (i) the Danish National Prescription Registry12 which holds information on purchase 
date, Anatomical Therapeutic Chemical [ATC] classification code, and package size for every 
prescription purchase in Denmark since 1994; (ii) the Danish National Patient Register13 established 
in 1977, which includes admission/discharge date, and discharge International Classification of 
Diseases [ICD] diagnoses for >99% of somatic hospital admissions in Denmark; and (iii) the 
Danish Civil Registration System14 which holds information on sex, date of birth, vital and 
emigration status.  
 
Study population 
We identified first-time purchases of dabigatran 110mg bid (D110) or dabigatran 150mg bid (D150) 
during the period August 1, 2011 (dabigatran market entry in Denmark) to May 30, 2013, alongside 
all purchases of warfarin during the period August 1 2009 to May 30 2013 (incorporating pre-
dabigatran warfarin purchases in order to determine VKA-experience status). We excluded 
purchases not preceded by a hospital diagnosis of AF, or preceded by a hospital diagnosis of mitral 
stenosis, venous thromboembolism, or valvular surgery, or preceded by phenprocoumon use. In 
accordance with the focus on secondary prevention, we excluded purchases not preceded by a 
hospital diagnosis of stroke/ transient ischemic attack. A person was considered VKA-naïve, 
respectively VKA-experienced, if the time since the last warfarin purchase was ≥2 years, 
respectively <2, years. A relatively long period was used in order to also reflect naivety in relation 
to treatment routine. 
From the purchase data, we defined a VKA-naïve stratum of all VKA-naïve subjects making a first-
time purchase of dabigatran. As controls in this stratum, we sampled the full population of VKA-
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naïve subjects making a first-time warfarin purchase. The baseline date in the VKA-naïve stratum 
was set to the date of first purchase.  
We next defined a VKA-experienced stratum of all VKA-experienced subjects purchasing 
dabigatran for the first time (switchers). Comparable controls were selected for each switcher by 
matched sampling among VKA-experienced warfarin controls. Specifically, 2 VKA-experienced 
warfarin users were matched to each switcher according to calendar month of purchase and duration 
of VKA-experience (up to 1 year; 1-5 years; more than 5 years). The baseline date in the VKA-
experienced stratum was set to the date of (first) purchase in the calendar month of inclusion.  
 
Endpoints and variable definitions 
Participants were followed until July 31 2013 in the Danish National Patient Register (using the 
10th Revision of ICD codes, ICD-10) for the occurrence of the following endpoints: ischemic 
stroke (I63, I64.9) or transient ischemic attack (G45); and fatal stroke, not including hemorrhagic 
stroke (ischemic stroke or transient ischemic attack followed by death within 30 days).  
Demographic data were obtained from the Danish Civil Registration System. Comorbidities and co-
medications (listed in Table 1) were ascertained from the Danish National Patient Registry and the 
Danish National Prescription Registry (for ICD-10 and ATC code definitions, see Supplementary 
Table 1). We combined covariate information into CHADS2 (Congestive heart failure, 
Hypertension, Age 75 years, Diabetes mellitus, and previous stroke or TIA)/CHA2DS2VASc 
(Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, previous Stroke/transient 
ischemic attack, Vascular disease, Age 65–74 years, and Sex category [female gender]) scores 15 for 
assessing stroke risk, and a HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, 
Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol) bleeding risk score16 
(definitions in Supplementary Table 2). 
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Statistical analysis 
Time-to-event analysis was used to compare the risk of stroke/ transient ischemic attack between 
treatment groups within the two VKA-experience strata (naïve/experienced), measuring risk time 
from baseline and until the relevant event, emigration, death, or July 31 2013, whichever came first.  
Crude cumulative incidences of stroke/ transient ischemic attack were calculated with the Aalen-
Johansen method under competing risk of death15. Cox regression was used to contrast event rates 
between the dabigatran users and warfarin controls within each of the VKA-experience strata. To 
address confounding by indication of treatment, regression analyses were adjusted for the baseline 
values of the following indications: age (continuous; cubic spline); components of CHA2DS2VASc 
and HAS-BLED (binary); and months since August 2011 (continuous; cubic spline). In the VKA-
experienced stratum, we also adjusted for time since initiation of VKA therapy (continuous; cubic 
spline). 
We estimated 3-month persistence probabilities15, defining time of non-persistence as the time of 
treatment switching or >30 days discontinuation (ascertained from previous package sizes and a 
standard daily dose).  
A number of sensitivity/supplementary analyses were carried out. First, we repeated regression 
analyses after censoring individuals at the time of non-persistence in order to quantify the effect of 
continuous treatment (implicitly assuming censoring to be non-informative conditionally on 
baseline covariates). Second, to assess robustness to a more stringent endpoint definition (with 
presumably higher validity), regression analyses were also repeated when requiring endpoints to 
have been registered as the primary diagnosis in connection with hospitalization for at least one 
night. Lastly, we repeated a subset of the main analyses in the primary prevention group, i.e. the 
analogously defined two VKA-experience strata based on the subset of the warfarin/dabigatran 
purchase data that excluded subjects with a prior diagnosis of stroke/ transient ischemic attack. 
Stata/MP version 12.1 was used for the statistical analysis.  A two-sided P value <0.05 was 
considered as statistically significant.  
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Results 
Study population characteristics 
A flow chart of the study population is shown in Figure 1. In the VKA-naïve stratum, we included 
1,439 patients with atrial fibrillation and a history of stroke/ transient ischemic attack making a 
first-time dabigatran purchase; alongside 1,825 patients making a first-time warfarin purchase 
(controls). In the VKA-experienced stratum, 959 dabigatran switchers where matched to 1,918 
warfarin controls (selected among 11,159 unique subjects with a total of 76,553 purchases). 
Baseline information is shown in Table 1. Within each of the VKA-experience strata, D110 users 
were older, with a median age over 80 (compared to median ages below 76 and 70 for warfarin, 
respectively  D150 users). Accordingly, D110 users also had a higher stroke and bleeding risk 
(according to CHADS2/CHA2DS2VASc and HAS-BLED scores).  There were slightly more 
females than males in the D110 group (55% to 56%), but not in the D150 and the warfarin group 
(36% to 44% females). Comparing between VKA-experience strata, the age and gender distribution 
was similar for each of the three treatments. Patients in the VKA-experienced stratum generally had 
higher CHADS2/CHA2DS2VASc scores but a similar or slightly decreased HAS-BLED score. 
There were substantially fewer clopidogrel users in the VKA-experienced stratum (3.0% to 5.8%) 
compared the VKA-naïve stratum (20.1% to 21.4%) in the VKA-naïve stratum; and also fewer 
aspirin users users (21.8% to 23.0%) than in the VKA-naïve stratum (34.8% to 43.0%). 
 
Stroke and transient ischemic attacks 
The average follow-up time was 12.6 months (standard deviation: 4.5 months). Plots of crude 
cumulative incidences for the composite endpoint of stroke/ transient ischemic attack (Figure 2) 
showed that, in the VKA-naïve stratum, D110 users had the lowest risk and D150 the highest risk, 
with the risk increasing more rapidly in the early follow-up period. The stroke risk in the VKA-
experienced stratum was lower overall compared to the VKA-naïve stratum: within this stratum, 
warfarin users had the lowest and D110 users the highest risk.  
In the VKA-naïve stratum (‘new starters’), crude annual event rates of stroke/ transient ischemic 
attack ranged from 14.0% to 20.0% (Table 2). For the composite endpoint stroke/TIA, adjusted 
event rates showed a significant 36% reduction among D110 users in compared to warfarin (hazard 
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ratio [HR] 0.64, 95% confidence interval [CI]: 0.50-0.80) but similar rates for D150 users (HR 0.92, 
95% CI: 0.73-1.15). When investigating stroke and transient ischemic attack separately, similar 
results were found, with slightly larger rate reductions relative to warfarin for the endpoint transient 
ischemic attack. Crude annual rates of fatal stroke/ transient ischemic attack (not shown in Table 2) 
were generally low, ranging from 0.3% to 1.2%.  
Turning to the VKA-experienced stratum (‘switchers’), crude annual event rates of stroke/ transient 
ischemic attack were overall substantially lower than in the VKA-naïve stratum, ranging from 4.8% 
to 10.8% (Table 2). For stroke/TIA, we saw a significant doubling of the event rate of for both 
D110 and D150 compared to warfarin (D110 HR 1.99, 95% CI: 1.42-2.78; D150 HR 2.34, 95% CI: 
1.60-3.41). When considering stroke and transient ischemic attack separately, comparably sized 
increases in adjusted rates for dabigatran relative to warfarin. There were again few fatal strokes/ 
transient ischemic attack (not shown in Table 2), with crude annual rates ranging from 0.2% for 
D150 (0.3% for warfarin), to 2.3% for D110. 
Treatment persistence and supplementary analyses 
Persistence probabilities at 3 months were 87% (warfarin), 79% (D110), and 82% (D150) in the 
VKA-naïve stratum; 91% (warfarin), 81% (D110), and 84% (D150) in the VKA-experienced 
stratum.  
The persistence-adjusted Cox regression gave similar results as the main analysis (Supplementary 
Table 3); the increased rate of stroke/ transient ischemic attack with dabigatran relative to warfarin 
in the VKA-experienced stratum was slightly more pronounced in this analysis (D110 HR 2.33, 
95% CI: 1.53-3.55; D150 HR 2.48, 95% CI: 1.53-4.02). Upon censoring patients at time of non-
persistence, crude event rates in the VKA-naïve stratum were increased compared to the main 
analysis. The results of the second sensitivity analysis, featuring a more restrictive endpoint 
definition (Supplementary Table 4), were also consistent with the main analysis, although events 
rates were low. 
Repeating regression analyses in the primary prevention group (Supplementary Table 5) lead to 
similar rates of stroke/ transient ischemic attack across strata in the adjusted comparison of D150 
versus warfarin (VKA-naïve HR 0.98, 95% CI: 0.72-1. VKA-experienced HR: 0.83, 95% CI: 0.51-
1.35). In contrast, the rate for D110 was increased compared to warfarin in the VKA-experienced 
stratum, but not in the VKA-naïve (HR 1.86, 95% CI: 1.30-2.67 and HR 1.01, 95% CI: 0.74-1.37, 
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respectively). Of note, the primary prevention group was substantially younger than the secondary 
prevention group; and with lower stroke and bleeding risks, according to the 
CHADS2/CHA2DS2VASc and HAS-BLED scores, respectively (Supplementary Table 6).  
 
Discussion 
In this large register-based observational study of secondary stroke prevention among atrial 
fibrillation patients, we found similar effectiveness of dabigatran relative to warfarin for secondary 
prevention of stroke/ transient ischemic attack among ‘new starters’ on anticoagulant therapy. In 
contrast, we found a doubling of the stroke/ transient ischemic attack rate among ‘switchers’ to both 
dabigatran doses compared to persisters on warfarin. The overall stroke risk was generally higher in 
‘new starters’ on anticoagulant therapy regardless of therapy. A supplementary analysis in the 
primary stroke prevention group indicated no differences in stroke risk relative to warfarin for both 
‘new starters’ and ‘switchers’ on dabigatran, except for switchers to D110 who were at an increased 
risk of stroke/TIA.   
Altogether, our study suggests that caution and vigilance is needed when switching prior VKA-
experienced atrial fibrillation patients to dabigatran, especially for patients who are able to 
consistently maintain a high average time in therapeutic range. The extent to which the increased 
risk with dabigatran can be attributed to the intervention of switching is, however, not clear, 
particularly in the light of the findings from randomized trials. A predefined sub-study of RE-LY 
among participants with prior stroke/ transient ischemic attack found no significant difference 
between both dabigatran doses and warfarin in relation to the risk of stroke or systemic embolism16. 
Of note, there were several key differences from the present study: for example, prior VKA 
experience was not explicitly accounted for, participants were much younger, and recurrent stroke 
rates were lower. However, in the phase III trial on rivaroxaban versus warfarin17,18, a marked 
increase in cardiovascular events were seen during the transition to open label therapy for patients 
switching therapy at the end of the trial.  Meta-analyses and indirect comparisons have thus far 
confirmed the non-inferiority findings from the RE-LY subgroup studies7,19.Divergent findings in 
an observational study necessitate caution since design limitations can easily induce spurious 
results. Bias due to residual or unmeasured confounding by indication is a serious concern: an 
apparent treatment effect may simply reflect unaccounted indications for which the treatment was 
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administered. In the present study, clinicians may have been more likely to switch patients with 
difficulties maintaining a high time in therapeutic range. Since INR measurements are not available 
from the registries, we were unable to investigate this. While confounding bias alone is a viable 
explanation for our findings, it does raise new questions about the sources of such confounding. 
Indeed, in our analyses, we adjusted for variables that a priori would be expected to be strong 
confounders, yet we observed only a modest change in the crude point estimates. If confounding 
bias were to completely explain our findings, we speculate that there would either have to be many 
unmeasured confounders with a moderate effect or a few very strong unmeasured confounders. As a 
crude, quantitative assessment, a binary unmeasured confounder with a prevalence of 80% among 
switchers and 20% among warfarin persisters would only completely explain a Cox model HR of 
1.7 if the confounder triples the rate of stroke/ transient ischemic attack 20.  
A combination of confounding bias and (causal) effects due to treatment switching may also explain 
our divergent findings. Patients may be less protected in the early period following a switch from 
warfarin, for example because of ‘latent’ strokes previously prevented by warfarin and appearing 
after warfarin discontinuation - or simply because the patient is less familiar with the new treatment. 
Indeed, plots of crude incidences lend some support to the observation that the early period after 
switching is a higher risk period. Lastly, irrespective of whether or not our findings are partly 
attributable to drug-related causal effects, they still convey the important message that real world 
prior stroke/ transient ischemic attack ‘switchers’ from warfarin to dabigatran represent a high risk 
group. Our study may offer a valuable insight for a future randomized trial of outcomes after 
treatment switching. 
We conclude by commenting on the overall stroke risk differences between VKA-naïve and VKA-
experienced users which were clearly visible from Figure 2. These are likely to be attributable to the 
‘healthy user’ selection inherent in the definition of the VKA-experienced stratum: to be included in 
the VKA-experienced stratum, one has to survive the time from treatment initiation to study 
inclusion with at most one stroke. The differences apparent in Figure 2 emphasize the 
appropriateness of treating the VKA-naïve and VKA-experienced stratum separately. 
Limitations of the present observational study in terms of confounding bias have already been 
discussed, with the lack of INR measurements being a particular concern. Also, the accuracy of the 
proposed “intention-to-treat approach” relies on patients actually taking their drugs, as is the case 
for all comparative effectiveness studies. While the validity of an ischemic stroke diagnosis is high 
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in the Danish Registry of Patients21, misclassification is also a relevant limitation (reassuringly, a 
more stringent definition of endpoints lead to results consistent with our main analysis). Lastly, one 
should be aware of the limitations of a comparative effectiveness study of a newly-marketed drug 
such as dabigatran; these can include channeling of selected patient groups towards the new drug, as 
well as time-varying user population characteristics22. Strengths of the study include the use of large 
‘real world’ atrial fibrillation population, the long follow-up period, and the completeness of the 
registries. 
 
Conclusion 
In this nationwide cohort study, we found that for patients with a history of stroke/ transient 
ischemic attack who are VKA-naïve, both dabigatran doses provided similar protection to warfarin 
against recurrent stroke/TIA. Among VKA-experienced patients, the risk of recurrent stroke/ 
transient ischemic attack was significantly increased compared to continued warfarin usage. 
Although clinical implications from observational data must be drawn carefully, our findings stress 
the importance of caution and vigilance when switching prior VKA-experienced atrial fibrillation 
patients to dabigatran, especially for patients with prior good quality anticoagulation as reflected by 
a high time in therapeutic range.  
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Figure legends 
Figure 1. Flow chart showing how the study population was obtained from prescription 
purchase data.  
Boxes show number of purchases with number of unique subjects in parentheses. The final study 
population with prior stroke is displayed in dashed boxes. In the VKA-experienced stratum, 
warfarin purchasers were sampled in a 2:1 ratio for each switcher to dabigatran (according to 
calendar month of purchase and duration of VKA-experience). 
 
Figure 2. Crude cumulative incidence of the composite endpoint of stroke or transient 
ischemic attack, according to Vitamin K antagonist-experience and current treatment. 
  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
Table 1. Participant characteristics at baseline, according to VKA-experience stratum and 
current treatment. 
 
Vitamin K antagonist-naïve Vitamin K antagonist-experienced 
 
Warfarin Dabigatran 
110 mg 
Dabigatran 
150 mg 
Warfarin Dabigatran
110 mg 
Dabigatran 
150 mg 
Subjects, no. 1,825 793 646 1,918 547 412 
Age, years 
      
   Median 76 83 69 75 82 70 
   Interquartile range 69-82 78-87 64-74 69-82 78-86 65-74 
Age ≥ 65 yrs, % 84.9 96.1 70.0 85.5 97.3 74.8 
Age ≥ 75 yrs, % 52.9 82.8 18.6 51.3 84.8 20.9 
Female sex, % 44.0 56.2 35.9 38.7 55.0 38.8 
Risk scores at baseline 
CHADS2, mean (SD)a 3.15 (0.90) 3.41 (0.79) 2.64 (0.74) 3.19 (0.92) 3.51 (0.79) 2.91 (0.92) 
CHA2DS2VASc, mean (SD)b 4.76 (1.40) 5.22 (1.14) 3.87 (1.19) 4.71 (1.33) 5.35 (1.11) 4.34 (1.31) 
HAS-BLED, mean (SD)c 3.11 (1.04) 3.18 (0.89) 2.72 (1.00) 2.81 (0.96) 2.99 (0.95) 2.72 (0.99) 
Comorbidities at baseline 
Prior ischemic stroke 75.3 81.2 74.9 75.7 82.1 76.5 
Prior transient ischemic attack 36.3 32.0 35.8 37.2 32.4 34.7 
Prior bleeding, % 16.2 20.9 13.0 19.2 24.5 19.7 
Diabetes, % 16.1 15.4 13.0 18.0 14.1 20.6 
Hypertension, % 36.4 33.0 29.6 37.7 36.7 38.1 
Abnormal renal function, % 9.5 3.9 0.9 6.0 3.3 3.2 
Abnormal hepatic function, % 0.4 0.8 0.0 0.1 0.5 0.0 
Prior congestive heart failure, % 9.8 10.2 2.9 11.8 15.5 11.7 
Prior myocardial infarction, 
   unstable angina  
   or cardiac arrest ,% 17.6 17.5 8.4 19.8 25.0 22.1 
Medications at baseline 
Aspirin, % 43.0 42.7 34.8 23.0 25.6 21.8 
Clopidogrel, % 21.4 20.1 20.3 3.0 6.4 5.8 
NSAID, % 5.2 4.2 4.8 4.3 4.4 4.9 
Clopidogrel and aspirin/NSAID, 
% 
7.7 6.2 5.0 0.4 2.0 1.5 
a.CHADS2: score ranging from 0-5 which reflect the stroke risk in atrial fibrillation patients not in anticoagulant therapy 
(see Supplementary Table 2). b.CHA2DS2VASc: score ranging from 0-9 which reflect the risk of stroke in atrial 
fibrillation patients not in anticoagulant therapy (see Supplementary Table 2). c.HAS-BLED: score ranging from 0-9 
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which reflect the risk of bleeding in atrial fibrillation patients undergoing anticoagulant therapy (see Supplementary 
Table 2). Abbreviation: SD = Between-subjects standard deviation, NSAID = Non-steroidal anti-inflammatory drugs 
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Table 2. Event rates and Cox hazard ratios for the various endpoints, according to VKA-
experience stratum and current treatment. 
 
 
No. 
events 
Rate, 
% per year 
Crude hazard ratio  
(95% CI) 
Adjusteda hazard 
ratio 
Vitamin K antagonist-naïve stratum     
Stroke or transient ischemic attack     
    Warfarin 300 18.0 1 (reference) 1 (reference) 
    Dabigatran 110mg 93 14.0 0.74 (0.59-0.93) 0.67 (0.52-0.86) 
    Dabigatran 150mg 102 18.2 0.99 (0.78-1.24) 1.02 (0.80-1.30) 
Stroke     
    Warfarin 231 13.4 1 (reference) 1 (reference) 
    Dabigatran 110mg 82 12.2 0.85 (0.67-1.10) 0.74 (0.56-0.97) 
    Dabigatran 150mg 82 14.1 1.02 (0.79-1.31) 1.10 (0.83-1.44) 
Transient ischemic attack     
    Warfarin 84 4.6 1 (reference) 1 (reference) 
    Dabigatran 110mg 17 2.4 0.49 (0.29-0.83) 0.48 (0.28-0.83) 
    Dabigatran 150mg 25 4.0 0.85 (0.55-1.34) 0.79 (0.49-1.28) 
     
Vitamin K antagonist-experienced 
stratum 
    
Stroke or transient ischemic attack     
    Warfarin 133 5.9 1 (reference) 1 (reference) 
    Dabigatran 110mg 59 10.8 1.77 (1.30-2.40) 1.54 (1.11-2.13) 
    Dabigatran 150mg 45 9.2 1.57 (1.12-2.19) 1.79 (1.25-2.56) 
Stroke     
    Warfarin 102 4.5 1 (reference) 1 (reference) 
    Dabigatran 110mg 52 9.4 2.03 (1.45-2.84) 1.73 (1.21-2.47) 
    Dabigatran 150mg 33 6.6 1.49 (1.00-2.20) 1.79 (1.18-2.72) 
Transient ischemic attack     
    Warfarin 39 1.7 1 (reference) 1 (reference) 
    Dabigatran 110mg 14 2.4 1.42 (0.77-2.62) 1.30 (0.68-2.5+) 
    Dabigatran 150mg 15 2.9 1.73 (0.95-3.14) 1.72 (0.92-3.22) 
a
 Estimates adjusted for: CHA2DS2VASc and HAS-BLED components (binary); age (cubic spline); months since august 
2011 (cubic spline); time since initiation of VKA therapy (if applicable; cubic spline). Abbreviation: CI = confidence 
interval.  
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689,794 (98,583)41,613 (41,613)
562,652 (78,775)35,633 (35,633)
29,805 (4 191)2,338 (2,338)
19,825 (4 356)378 (378)
76,553 (11,159)
547 (547)
412 (412)
1,825 (1,825)
793 (793)
646 (646)
No prior stroke
No prior atrial fibrillation
Other exclusion criteria*
Warfarin (all)
Dabigatran 110 mg (first)
Dabigatran 150 mg (first)
VKA-experiencedVKA-naïve
1,918 (1,918)Warfarin (2:1 matched)
*Prior hospital diagnosis of mitral stenosis; venous thromboembolism; valvular
surgery; or prior phenprocoumon use.
Abbreviations: VKA: Vitamin K antagonist
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Supplementary Table 1. ICD-10/ATC-codes used to identify comorbid conditions and co-
medication 
 
aWe identified subjects with hypertension from combination treatment with at least two of the following classes of antihypertensive  
drugs:  
 
I. Alpha adrenergic blockers (C02A, C02B, C02C) 
II. Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52) 
III. Vasodilators (C02DB, C02DD, C02DG, C04, C05)  
IV. Beta blockers (C07) 
V. Calcium channel blockers (C07F, C08, C09BB, C09DB) 
VI. Renin-angiotensin system inhibitors (C09). 
 
 
International Classification of Diseases  
10th revision (ICD-10) code 
Anatomical Therapeutic 
Chemical (ATC) code 
Condition   
   Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 and C03C 
   Left ventricular dysfunction I50.1; I50.9  
   Hypertension  See specified definitiona 
   Diabetes mellitus E10.0; E10.1; E10.9; E11.0; E11.1; E11.9 or A10 
   Ischemic stroke I63; I64.9  
   Systemic embolism I74  
   Transient ischemic attack G45  
   Aortic plaque I70.0  
   Peripheral arterial disease  I70.2-I70.9; I71; I73.9  
   Myocardial infarction I21-I23  
   Unstable angina I20  
   Cardiac arrest I46  
   Abnormal renal function I12; I13; N00-N05; N07; N11; N14; N17-N19; Q61  
   Abnormal hepatic function B15.0; B16.0; B16.2; B19.0; K70.4; K72; K76.6; 
I85 
 
   Bleeding I60-I62; D62; J94.2; H11.3; H35.6; H43.1; N02; 
N95; R04; R31; R58; K25.0; K26.0; K27.0; K28.0; 
K29.0; S06.3C; S06.4; S06.5; S06.6 
 
   Alcohol intake E22.4; E52.9A; F10; G31.2; G62.1; G72.1; I42.6; 
K29.2; K70; K86.0; L27.8A; O35.4M; T51; Z71.4; 
Z72.1 
 
   Atrial fibrillation I48  
Medication   
   Dabigatran  B01AE07 
   Warfarin 
 
B01AA03 
   Aspirin  B01AC06 
   Clopidogrel  B01AC04 
   Phenprocoumon  B01AA04 
   Non-steroidal  
     anti-inflammatory drugs 
 M01A 
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Supplementary Table 2. Definition of risk scores. 
 
Risk score Points if present 
CHADS2a  
   Congestive heart failure 1 
   Hypertension 1 
   Age ≥ 65 years 1 
   Diabetes mellitus 1 
   Stroke (ischemic stroke or transient ischemic attack,) 2 
CHA2DS2VAScb   
   Congestive heart failure or Left Ventricular Dysfunction 1 
   Hypertension 1 
   Age ≥ 65 years 1 
      Age ≥ 75 years 1 
   Diabetes mellitus 1 
   Stroke (ischemic stroke, transient ischemic disease or systemic embolism) 2 
   Vascular disease (myocardial infarction, peripheral arterial disease, or aortic plaque) 1 
   Sex category (female)  1 
HAS-BLEDc  
   Hypertension 1 
   Abnormal renal function 1 
      Abnormal hepatic function 1 
   Stroke (ischemic stroke or transient ischemic attack) 1 
   Bleeding 1 
   Labile international normalized ratiod  1 
   Elderly age (≥ 65 years) 1 
   Drugs (aspirin, clopidogrel, or non-steroidal anti-inflammatory drugs) 1 
      Alcohol intake 1 
 
aReflects stroke risk in atrial fibrillation patients not in anticoagulant therapy (Gage BF, van Walraven C, Pearce L, et 
al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. 
Circulation 2004;110(16):2287-92) 
bReflects stroke risk in atrial fibrillation patients not in anticoagulant therapy (Lip GYH, Nieuwlaat R, Pisters R, Lane 
DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation 
using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72) 
cReflects bleeding risk in atrial fibrillation patients undergoing anticoagulant therapy (Pisters R, Lane DA, Nieuwlaat R, 
de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding 
in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100) 
dNot included due to unavailable information 
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Supplementary Table 3. Persistence-adjusted (censoring participants at the time of non-
persistence) event rates and Cox hazard ratios for the various endpoints, according to VKA-
experience stratum and current treatment. 
 
 
 
No. 
events 
Rate, 
% per year 
Crude hazard ratio  
(95% CI) 
Adjusteda hazard ratio 
(95% CI) 
Vitamin K antagonist-naïve stratum     
Stroke or transient ischemic attack     
   Warfarin 223 23.2 1 (reference) 1 (reference) 
   Dabigatran 110mg 69 17.2 0.73 (0.56-0.95) 0.69 (0.52-0.92) 
   Dabigatran 150mg 84 23.9 1.08 (0.84-1.39) 1.13 (0.86-1.49) 
Stroke 
    
   Warfarin 174 17.7 1 (reference) 1 (reference) 
   Dabigatran 110mg 60 14.8 0.82 (0.61-1.09) 0.75 (0.55-1.03) 
   Dabigatran 150mg 66 18.1 1.08 (0.81-1.43) 1.19 (0.87-1.61) 
Transient ischemic attack 
    
   Warfarin 55 5.3 1 (reference) 1 (reference) 
   Dabigatran 110mg 11 2.6 0.48 (0.25-0.91) 0.50 (0.26-0.96) 
   Dabigatran 150mg 21 5.4 1.06 (0.64-1.77) 0.94 (0.55-1.63) 
 
    
Vitamin K antagonist-experienced stratum 
    
Stroke or transient ischemic attack 
    
   Warfarin 95 6.8 1 (reference) 1 (reference) 
   Dabigatran 110mg 41 12.9 1.82 (1.26-2.63) 1.5 (1.01-2.23) 
   Dabigatran 150mg 28 10.3 1.49 (0.98-2.27) 1.67 (1.07-2.61) 
Stroke 
    
   Warfarin 73 5.2 1 (reference) 1 (reference) 
   Dabigatran 110mg 35 11.0 2.03 (1.36-3.04) 1.59 (1.03-2.45) 
   Dabigatran 150mg 21 7.6 1.44 (0.89-2.34) 1.81 (1.08-3.04) 
Transient ischemic attack 
    
   Warfarin 23 1.6 1 (reference) 1 (reference) 
   Dabigatran 110mg 9 2.7 1.64 (0.76-3.55) 1.59 (0.69-3.69) 
   Dabigatran 150mg 8 2.8 1.71 (0.76-3.81) 1.41 (0.61-3.26) 
aEstimates adjusted for: CHA2DS2VASc and HAS-BLED components (binary); age (cubic spline); months since august 
2011 (cubic spline); time since initiation of VKA therapy (if applicable; cubic spline) 
 
Abbreviations: CI = confidence interval 
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Supplementary Table 4. Event rates and Cox hazard ratios for the various endpoints, 
requiring endpoints to have been registered as the primary diagnosis in connection with 
hospitalization for at least one night, according to VKA-experience stratum and current 
treatment. 
 
 
 
No. 
events 
Rate, 
% per year 
Crude hazard ratio  
(95% CI) 
Adjusteda hazard ratio 
(95% CI) 
Vitamin K antagonist-naïve stratum     
Stroke or transient ischemic attack     
   Warfarin 97 5.3 1 (reference) 1 (reference) 
   Dabigatran 110mg 33 4.6 0.84 (0.56-1.25) 0.69 (0.46-1.03) 
   Dabigatran 150mg 23 3.6 0.67 (0.43-1.06) 0.77 (0.48-1.25) 
Stroke 
    
   Warfarin 66 3.5 1 (reference) 1 (reference) 
   Dabigatran 110mg 26 3.6 0.98 (0.62-1.54) 0.71 (0.45-1.13) 
   Dabigatran 150mg 12 1.9 0.51 (0.28-0.95) 0.62 (0.32-1.19) 
Transient ischemic attack 
    
   Warfarin 36 1.9 1 (reference) 1 (reference) 
   Dabigatran 110mg 9 1.2 0.62 (0.30-1.27) 0.61 (0.30-1.24) 
   Dabigatran 150mg 12 1.9 0.95 (0.49-1.83) 0.99 (0.50-1.98) 
 
    
Vitamin K antagonist-experienced stratum 
    
Stroke or transient ischemic attack 
    
   Warfarin 59 2.6 1 (reference) 1 (reference) 
   Dabigatran 110mg 31 5.5 2.10 (1.36-3.25) 1.49 (0.94-2.36) 
   Dabigatran 150mg 20 3.9 1.53 (0.92-2.53) 2.08 (1.20-3.59) 
Stroke 
    
   Warfarin 32 1.4 1 (reference) 1 (reference) 
   Dabigatran 110mg 23 4.0 2.85 (1.67-4.88) 1.83 (1.04-3.21) 
   Dabigatran 150mg 11 2.1 1.55 (0.78-3.07) 2.71 (1.28-5.77) 
Transient ischemic attack 
    
   Warfarin 30 1.3 1 (reference) 1 (reference) 
   Dabigatran 110mg 9 1.6 1.20 (0.57-2.53) 1.04 (0.47-2.30) 
   Dabigatran 150mg 10 1.9 1.48 (0.72-3.03) 1.50 (0.71-3.19) 
aEstimates adjusted for: CHA2DS2VASc and HAS-BLED components (binary); age (cubic spline); months 
since august 2011 (cubic spline); time since initiation of VKA therapy (if applicable; cubic spline) 
 
Abbreviations: CI = confidence interval 
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Supplementary Table 5. Event rates and Cox hazard ratios for the various endpoints, 
according to VKA-experience stratum and current treatment, among atrial fibrillation 
patients with no history of stroke or transient ischemic attack.  
 
 
 
 
 
 
 
 
 
 
 
Vitamin K antagonist-naïve Vitamin K antagonist-experienced 
 
Warfarin Dabigatran 
110 mg 
Dabigatran  
150 mg 
Warfarin Dabigatran 
110 mg 
Dabigatran 
150 mg 
Subjects, no. 9,216 2,236 3,363 6,018 1,484 1,797 
Age, yrs 
   Median 72 81 67 74 81 68 
   Interquartile range 65-79 76-86 62-72 67-80 76-85 64-73 
Female sex, % 41.4 54.7 36.7 37.9 54 34.4 
Risk scores at baseline 
HAS-BLED, mean (SD) 0.96 (0.88) 1.38 (0.82) 0.61 (0.74) 1.16 (0.90) 1.54 (0.87) 0.91 (0.86) 
CHADS2, mean (SD) 2.41 (1.43) 3.15 (1.17) 1.78 (1.19) 2.61 (1.33) 3.35 (1.20) 2.19 (1.28) 
CHA2DS2VASc, mean (SD) 1.73 (1.06) 2.01 (0.90) 1.50 (1.02) 1.66 (0.91) 1.94 (0.87) 1.63 (1.00) 
Stroke or  transient 
ischemic attack during 
followup No. events  194 56 55 98 49 21 
Rate, % per year 2.0 2.7 1.7 1.2 3.1 0.9 
Crude estimates 
   Hazard ratio 1 (reference) 1.31 0.83 1 (reference) 2.47 0.75 
95% confidence interval 0.97-1.77 0.61-1.13 1.75-3.48 0.47-1.2 
Adjusteda estimates 
   Hazard ratio 1 (reference) 0.99 1.05 1 (reference) 1.73 1.04 
   95% confidence interval 0.72-1.36 0.76-1.45 1.2-2.48 0.64-1.7 
 
 
aEstimates adjusted for: CHA2DS2VASc and HAS-BLED components (binary); age (cubic spline); months since august 
2011 (cubic spline); time since initiation of VKA therapy (if applicable; cubic spline) 
 
 
CHADS2: score ranging from 0-5 which reflect the stroke risk in atrial fibrillation patients not in anticoagulant therapy  (see 
Supplementary Table 2). 
CHA2DS2VASc: score ranging from 0-9 which reflect the risk of stroke in atrial fibrillation patients not in anticoagulant 
therapy (see Supplementary Table 2). 
HAS-BLED: score ranging from 0-9 which reflect the risk of bleeding in atrial fibrillation patients undergoing 
anticoagulant therapy (see Supplementary Table 2).  
SD: Between-subjects standard deviation 
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Clinical Significance 
 
This study revealed, that in clinical practice, vitamin K antagonist-experienced patients with a 
history of stroke or transient ischemic attack who switch to dabigatran therapy may have an 
increased rate of a recurrent stroke compared to patients persisting with vitamin K antagonist 
therapy. 
 
